Eggermont

Full Professor

Biography

lid raad van bestuur	Prinses Maxima Centrum voor Kinderoncologie	1-10-2019
adviseur	CCCMünchen	1-1-2022
adviseur	Deutsche Krebshilfe	1-9-2019
adviseur	DKFZ-Heidelberg	1-1-2020
Editor-in-chief	Eur J Cancer	1-1-2020
chairman board	Fondation Cancer, B	1-1-2015
member	DSMB Melanoma Trials NKI-AvL	1-1-2018
board member	SAB Ludwig Cancer Inst Lausanne	1-1-2022
board member	EORTC Foundation Board	1-1-2011
IDMCimmuno member	IKR/AvL	1-1-2021
Advisory board	Agenus	1-1-2021
Advisory board/DSMB	Biocad	1-1-2020
Advisory board	BioInvent	1-1-2020
IDMC	BioNTech	1-1-2020
Advisory board	CatalYm	1-1-2022
Advisory board	Clover	1-1-2017
Advisory board	Ellipses	1-9-2021
Advisory board	Galecto	1-1-2019
Advisory board/IDMC	GSK	1-1-2020
Advisory board	IO Biotech	1-2-2022
Advisory board	Merck	1-1-2019
IDMC	Pfizer	1-6-2019
Advisory board	Sairopa	1-6-2021
Advisory board	Sellas	1-1-2018
Advisory board	SkylineDx	1-1-2020
Advisory board	TigaTx	1-7-2021
Advisory board	TTxDiscovery	1-10-2021
Lezingen Melanoma	Biocad, BMS, MSD	1-1-2021

Contact

aeggerm3@umcutrecht.nl

Pure profile

Recent publications

All publications

Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy Teresa Amaral, Eftychia Chatziioannou, Alica Nuebling, Lena Nanz, Tobias Sinnberg, Heike Niessner, Tim Arentsen, Romy Ruiter, Jvalini Dwarkasing, Alexander M Eggermont, Ulrike Leiter, Lukas Flatz, Stephan Forchhammer
European Journal of Cancer, 2025, vol. 220

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, Piotr Rutkowski, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Luis de la Cruz Merino, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Dirk Schadendorf, Federica de Galitiis, Matteo S Carlino, Reinhard Dummer, Peter Mohr, Amos Odeleye-Ajakaye, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander... Show all

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types Luigi Lim, Abigirl Machingura, Mekdes Taye, Madeline Pe, Corneel Coens, Francesca Martinelli, Ahu Alanya, Stéphanie Antunes, Dongsheng Tu, Ethan Basch, Jolie Ringash, Yvonne Brandberg, Mogens Groenvold, Alexander Eggermont, Fatima Cardoso, Jan Van Meerbeeck, Michael Koller, Winette T A Van der Graaf, Martin J B Taphoorn, Johan A F Koekkoek,... Show all

Perspectives on the role of "-Omics" in predicting response to immunotherapy Anna Maria Di Giacomo, Sumit Subudhi, Wim Vos, Massimo Andreatta, Santiago Carmona, Will McTavish, Barbara Seliger, Ramy Ibrahim, Michael Lahn, Michael Smith, Alexander Eggermont, Bernard A Fox, Michele Maio
European Journal of Cancer, 2025, vol. 220

Adjuvant Pembrolizumab in Stage II Melanoma Charles H. Yoon, Merrick I. Ross, Brian R. Gastman, Jason J. Luke, Paolo A. Ascierto, Georgina V. Long, Piotr Rutkowski, Muhammad Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion-Sileni, Dirk Schadendorf, Matteo S. Carlino, Yujie Zhao, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M M. Eggermont, Jeffrey... Show all

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, Lev Demidov, Brigitte Dreno, Reinhard Dummer, Alexander Eggermont, Ana Maria Forsea, Christoffer Gebhardt, Jeffrey E. Gershenwald, Omid Hamid, Christoph Hoeller, Lidija Kandolf, Roland Kaufmann, John M. Kirkwood, Celeste Lebbé, Georgina V. Long, Josep Malvehy, Salvador Martin-Algarra, Grant McArthur, Bart Neyns, Erika Richtig,... Show all

External positions

Lid SAB - Adviseren - Institut Jules Bordet

Lid SAB - Adviseren - EuroBio

Member Board - Adviseren - Trained Immunity Discovery

Lid IDMC - Adviseren - IQVIA

Lid IDMC - Adviseren - Pfizer

Lid SAB - Adviseren...